PMID- 37425378
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 1394-195X (Print)
IS  - 2180-4303 (Electronic)
IS  - 1394-195X (Linking)
VI  - 30
IP  - 3
DP  - 2023 Jun
TI  - Practise of Immunoglobulin Replacement Therapy in Primary and Secondary 
      Immunodeficiencies: A Single Centre Experience from Malaysia.
PG  - 112-121
LID - 10.21315/mjms2023.30.3.10 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) replacement therapy is increasingly 
      in demand. This study focused on the characteristics of IVIG usage and associated 
      factors toward the frequency status of IVIG among patients in Hospital Kuala 
      Lumpur. METHODS: A retrospective cross-sectional study was performed on patients 
      who received IVIG in Hospital Kuala Lumpur. Data were extracted from the request 
      forms for IVIG recorded in the Pharmacy Department from January 2018 until 
      December 2019. Chi-squared test and t-test analysis were used for statistical 
      analysis, and a P-value of < 0.05 was considered significant. RESULTS: A total of 
      482 patients received IVIG in Hospital Kuala Lumpur. There were 243 (50.4%) 
      females and 228 (47.3%) males with median age of the patients was 27 years old. 
      The highest indications for IVIG among all patients were hypogammaglobulinemia 
      and other deficiency states in 127 patients (26.3%). The most common indication 
      for one-off treatment in adults was hypogammaglobulinemia and other deficiency 
      states, 35%; whereas in paediatrics, it was Kawasaki disease, 20.3%. The highest 
      indication for regular therapy among adult patients was chronic inflammatory 
      demyelinating polyneuropathy (23.4%), while in paediatrics it was sepsis (31.1%). 
      The clinical category was associated with the frequency status of IVIG usage in 
      both adult and paediatric cohorts with P = 0.004 and P = 0.017, respectively. 
      CONCLUSION: There were significant differences between the indication of one-off 
      treatment and regular therapy among adult and paediatric patients. A national 
      guideline on the prescription of IVIG for patients is instantly needed to help 
      clinicians in prescribing IVIG appropriately.
CI  - (c) Penerbit Universiti Sains Malaysia, 2023.
FAU - Zahari, Nurul Hidayah
AU  - Zahari NH
AD  - Department of Clinical Medicine, Advanced Medical and Dental Institute, 
      Universiti Sains Malaysia, Pulau Pinang, Malaysia.
FAU - Abd Hamid, Intan Juliana
AU  - Abd Hamid IJ
AD  - Primary Immunodeficiency Diseases Group, Department of Clinical Medicine, 
      Advanced Medical and Dental Institute, Universiti Sains Malaysia, Pulau Pinang, 
      Malaysia.
FAU - Tuan Din, Sharifah Azdiana
AU  - Tuan Din SA
AD  - Department of Clinical Medicine, Advanced Medical and Dental Institute, 
      Universiti Sains Malaysia, Pulau Pinang, Malaysia.
FAU - Hashim, Ilie Fadzilah
AU  - Hashim IF
AD  - Primary Immunodeficiency Diseases Group, Department of Clinical Medicine, 
      Advanced Medical and Dental Institute, Universiti Sains Malaysia, Pulau Pinang, 
      Malaysia.
FAU - Zainudeen, Zarina Thasneem
AU  - Zainudeen ZT
AD  - Primary Immunodeficiency Diseases Group, Department of Clinical Medicine, 
      Advanced Medical and Dental Institute, Universiti Sains Malaysia, Pulau Pinang, 
      Malaysia.
FAU - Mohd Shariff, Noorsuzana
AU  - Mohd Shariff N
AD  - Health Community Department, Advanced Medical and Dental Institute, Universiti 
      Sains Malaysia, Pulau Pinang, Malaysia.
FAU - Ahmad, Nor Hafizah
AU  - Ahmad NH
AD  - Clinical Transfusion Department, National Blood Centre, Kuala Lumpur, Malaysia.
FAU - Tay, Chan Yen
AU  - Tay CY
AD  - Pharmacy Department, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20230627
PL  - Malaysia
TA  - Malays J Med Sci
JT  - The Malaysian journal of medical sciences : MJMS
JID - 101126308
PMC - PMC10325126
OTO - NOTNLM
OT  - chronic inflammatory demyelinating polyneuropathy
OT  - hypogammaglobulinemia
OT  - intravenous immunoglobulin
OT  - off-labelled indication
OT  - primary immunodeficiencies
COIS- Conflict of Interest None.
EDAT- 2023/07/10 06:42
MHDA- 2023/07/10 06:43
PMCR- 2023/06/01
CRDT- 2023/07/10 04:55
PHST- 2022/07/26 00:00 [received]
PHST- 2022/09/25 00:00 [accepted]
PHST- 2023/07/10 06:43 [medline]
PHST- 2023/07/10 06:42 [pubmed]
PHST- 2023/07/10 04:55 [entrez]
PHST- 2023/06/01 00:00 [pmc-release]
AID - 10mjms3003_oa [pii]
AID - 10.21315/mjms2023.30.3.10 [doi]
PST - ppublish
SO  - Malays J Med Sci. 2023 Jun;30(3):112-121. doi: 10.21315/mjms2023.30.3.10. Epub 
      2023 Jun 27.